Literature DB >> 16086118

VEGF significance in peritoneal recurrence from gastric cancer.

Keishiro Aoyagi1, Kikuo Kouhuji, Shojiro Yano, Motoshi Miyagi, Takuya Imaizumi, Jinryo Takeda, Kazuo Shirouzu.   

Abstract

BACKGROUND: In gastric cancer, the management of peritoneal dissemination in the Peritoneal cavity is extremely important; however, peritoneal dissemination in the final stage of gastric cancer remains untreatable. Peritoneal dissemination involves several steps, including tumor-cell attachment, invasion, and growth in the peritoneum. Many cytokines, growth factors, matrix metalloproteinases (MMPs), and angiogenic factors play important roles in these steps. So far, few studies have investigated the correlation, if any, between peritoneal dissemination and the angiogenic factor, vascular endothelial growth factor (VEGF).
METHODS: Immunohistochemical staining, using the avidin-biotin peroxidase complex method, was performed on slides of surgical specimens from 40 patients with stage II gastric cancer with serosal invasion, who underwent surgery at our hospital between 1990 and 2000. Anti-human VEGF rabbit polyclonal IgG was used as the primary antibody. VEGF expression was classified in one of four categories depending on the percentage of tumor-cell staining (P). VEGF expression was also classified in one of three categories depending on the staining intensity (I). The VEGF expression score was calculated as P x I.
RESULTS: There were ten patients with peritoneal recurrence. Of these, seven had macroscopic type-4 scirrhous-type gastric carcinoma. In the immunohistochemical study, the VEGF score of patients with peritoneal recurrence was 9.40 +/- 2.46; on the other hand, that of patients without peritoneal recurrence was 3.47 +/- 2.36. The VEGF score of patients with peritoneal recurrence was significantly higher than that of patients without peritoneal recurrence. In patients with macroscopic type 4, the VEGF score of those with peritoneal recurrence was 9.14 +/- 2.19, while on the other hand, that of the patients without peritoneal recurrence was 3.80 +/- 3.03. The VEGF score of these patients with peritoneal recurrence was significantly higher than that of those without peritoneal recurrence. The survival rate in the VEGF low-expression group was significantly higher than that in the VEGF high-expression group. Multivariate analysis showed that the VEGF score was a significant parameter of peritoneal recurrence.
CONCLUSION: These results suggested that VEGF was correlated with peritoneal metastasis from gastric cancer, and that VEGF was a useful indicator of peritoneal recurrence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086118     DOI: 10.1007/s10120-005-0329-4

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  21 in total

Review 1.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

2.  Adhesion molecules and TGF-beta1 are involved in the peritoneal dissemination of NUGC-4 human gastric cancer cells.

Authors:  T Nakashio; T Narita; S Akiyama; Y Kasai; K Kondo; K Ito; H Takagi; R Kannagi
Journal:  Int J Cancer       Date:  1997-03-04       Impact factor: 7.396

3.  Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line.

Authors:  Y Kondo; S Arii; A Mori; M Furutani; T Chiba; M Imamura
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

4.  Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.

Authors:  J Yoneda; H Kuniyasu; M A Crispens; J E Price; C D Bucana; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1998-03-18       Impact factor: 13.506

5.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

6.  Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.

Authors:  J A Nagy; E M Masse; K T Herzberg; M S Meyers; K T Yeo; T K Yeo; T M Sioussat; H F Dvorak
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

7.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

8.  Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.

Authors:  S Mesiano; N Ferrara; R B Jaffe
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

9.  The role of circulating IL-8 and VEGF protein in the progression of gastric cancer.

Authors:  Hiroyuki Konno; Manabu Ohta; Megumi Baba; Shohachi Suzuki; Satosi Nakamura
Journal:  Cancer Sci       Date:  2003-08       Impact factor: 6.716

10.  Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells.

Authors:  N Jonjić; G Peri; S Bernasconi; F L Sciacca; F Colotta; P Pelicci; L Lanfrancone; A Mantovani
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more
  23 in total

1.  Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.

Authors:  Wen-Jane Lee; Keng-Hsin Lan; Chiang-Ting Chou; Yu-Chiao Yi; Wei-Chih Chen; Hung-Chuan Pan; Yen-Chun Peng; Keh-Bin Wang; Yi-Ching Chen; Te-Hsin Chao; Hsing-Ru Tien; Wayne Huey Herng Sheu; Meei-Ling Sheu
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

2.  Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center.

Authors:  Sook Hee Hong; Yu Ri Shin; Sang Young Roh; Eun Kyoung Jeon; Kyo Yung Song; Cho Hyun Park; Hae Myung Jeon; Young Seon Hong
Journal:  Gastric Cancer       Date:  2012-08-17       Impact factor: 7.370

3.  Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis.

Authors:  Jing Chen; Tao Li; Yuanyuan Wu; Lijun He; Li Zhang; Tieliu Shi; Zhengfang Yi; Mingyao Liu; Xiufeng Pang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-15       Impact factor: 4.553

Review 4.  Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Shigenobu Emoto; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-02-01       Impact factor: 2.549

5.  The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer.

Authors:  Seong-Eun Kim; Ki-Nam Shim; Sung-Ae Jung; Kwon Yoo; Joo Ho Lee
Journal:  Gut Liver       Date:  2009-06-30       Impact factor: 4.519

6.  Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection.

Authors:  Long Sun; Huang-Yang Ye; Ying-Hong Zhang; Yong-Song Guan; Hua Wu
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

7.  Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model.

Authors:  Takuya Imaizumi; Keishiro Aoyagi; Motoshi Miyagi; Kazuo Shirouzu
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

8.  Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma.

Authors:  Mansour-S Al-Moundhri; A Al-Shukaili; M Al-Nabhani; B Al-Bahrani; I-A Burney; A Rizivi; S-S Ganguly
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

9.  Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer.

Authors:  Keishiro Aoyagi; Kikuo Kouhuji; Motoshi Miyagi; Junya Kizaki; Taro Isobe; Kousuke Hashimoto; Kazuo Shirouzu
Journal:  World J Crit Care Med       Date:  2013-11-04

10.  Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis.

Authors:  Gordana Jakovljević; Srana Culić; Jasminka Stepan; Aleksandra Bonevski; Sven Seiwerth
Journal:  J Exp Clin Cancer Res       Date:  2009-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.